Evaluation of renal and hematologic toxicities of 212Pb-VMT-alpha-NET to inform the safety of alpha-particle therapy for neuroendocrine tumors

被引：0

|

作者：

Lee, D. ^{[1
]}

Li, M. ^{[2
]}

Liu, D. ^{[3
]}

Baumhover, N. ^{[1
]}

Sagastume, E. A. ^{[2
]}

Marks, B. ^{[2
]}

Graves, S. A. ^{[1
]}

Zepeda-Orozco, D. ^{[4
]}

Johnson, F. L. ^{[2
]}

Menda, Y. ^{[1
]}

Bushnell, D. L. ^{[1
]}

Schultz, M. K. ^{[1
]}

机构：

[1] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA

[2] Viewpoint Mol Targeting Inc, Coralville, IA USA

[3] Univ Iowa, Stead Family Dept Pediat, Iowa City, IA USA

[4] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2021年 / 33卷

关键词：

prrt; alpha-particle therapy; pb-212; vmt-alpha-net; toxicity;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

K23

引用

收藏

页码：190 / 190

页数：1

相关论文

共 23 条

[21] First clinical experience using targeted alpha-emitter therapy with 212Pb-DOTAMTATE (AlphaMedix™) in patients th SSTR(+) neuroendocrine tumors.
Delpassand, Ebrahim
Tworowska, Izabela
Shanoon, Farah
Nunez, Rodolfo
Ii, Leo Flores
Muzammil, Ali
Stallons, Tania
Saidi, Amal
Torgue, Julien
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[22] De novo discovery and preclinical evaluation of cyclic radiopeptide [203/212Pb]Pb-PSV-359 targeting human fibroblast activation protein for alpha-particle radiotherapy in cancers
Cagle, Brianna
Baumhover, Nicholas
Vance, Ivy
Liu, Dijie
Rodman, Sam
Kalen, Amanda
Sagastume, Edwin
Johnson, Frances
Schultz, Michael
Li, Mengshi
JOURNAL OF NUCLEAR MEDICINE, 2024, 65
[23] Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR plus GEP-NETs): A phase 2 study
Strosberg, Jonathan R.
Naqvi, Shagufta
Cohn, Allen Lee
Delpassand, Ebrahim
Wagner, Volker Jean
Torgue, Julien
Woloski, Rachel
Manuel, Allison
Maluccio, Mary Alice
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)